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outcome in MM patients. Between January 2003 and September
2004, 13 MM patients received GM-CSF and IFN-	 therapy
following ASCT. IFN-	 was started within 120 days after ASCT at
a dose of 1 million units and increased as tolerated to 4 million
units subcutaneously 3  per week. GM-CSF was started at 125
g/m2day subcutaneously on the same days with IFN-	. The
combination therapy continued for 1 year, after which GM-CSF
was stopped. Ten patients receiving this combination therapy (me-
dian age, 61 years) were evaluable for analysis. Disease status at the
time of enrollment was complete remission in 1 patient, partial
remission in 4 patients, and very good partial remission in 5
patients. Six patients had stage III and 4 had stage II, with only 1
in renal failure. Median follow-up from last ASCT was 16 months.
Median duration of combination therapy was 7.5 months (range,
1–12 months). The median tolerated dose of IFN-	 was 4 million
units, although 2 patients had a permanent dose reduction to 2 or
3 million units due to ﬂu-like symptoms. None of the patients
dropped from the trial secondary to myelosuppression. Three
patients dropped out due to persistent ﬂu-like symptoms or ele-
vated liver function tests secondary to IFN-	, 2 patients dropped
out due to disease progression, and 1 patient had a GM-CSF dose
reduction due to leukocytosis. Median PLT count and ANC at 3
months were 136,000/L and 3800/L, respectively. One patient
required Procrit therapy. All patients received GM-CSF and
IFN-	 therapy for a minimum of 34 days. Two patients improved
to CR from PR and VGPR, 2 patients progressed, 5 patients
remained stable, and 1 patient was lost to follow-up. Using the
method of Kaplan and Meier, median PFS and OS for the whole
group have not been reached. In a previous analysis of 25 similar
patients who received a median of 8 months of IFN-	–only main-
tenance therapy (median tolerated dose of 3 million units), 10
patients had to discontinue therapy due to myelosuppression. In
conclusion, the addition of GM-CSF to IFN-	 is well tolerated
and is very effective in preventing IFN-induced myelosuppression.
It is too early to tell whether a survival beneﬁt will be realized.
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A PHASE II STUDY OF XCELLERATED T CELLS IN PATIENTS WITH RE-
LAPSED OR REFRACTORY INDOLENT NON-HODGKIN’S LYMPHOMA (NHL)
Gribben, J.G.1, Bartlett, N.L.2, Stephenson, J.J.3, Milder, M.S.4,
Boccia, R.V.5, Redfern, C.6, Mizuno, V.M.7, Berenson, R.J.7,
Frohlich, M.W.7 1Dana Farber Cancer Institute, Boston, MA; 2Wash-
ington University School of Medicine, St. Louis, MO; 3Cancer Centers of
the Carolinas, Greenville, SC; 4The Swedish Cancer Institute, Seattle,
WA; 5Center for Cancer & Blood Disorders, Bethesda, MD; 6Sharp
Healthcare, San Diego, CA; 7Xcyte Therapies, Inc., Seattle, WA.
Background: T cells can be activated and expanded ex vivo using
the Xcellerate™ process, in which peripheral blood mononuclear
cells (PBMCs) are incubated with anti-CD3 and anti-CD28 anti-
body–coated magnetic beads (Xcyte™ Dynabeads). In an ongo-
ing trial of Xcellerated t cells in subjects with chronic lymphocytic
leukemia, marked and sustained reductions in lymphadenopathy
and splenomegaly were observed. This study is designed to deter-
mine whether similar effects can be observed in subjects with
indolent NHL. Methods: Subjects must have relapsed or refrac-
tory indolent NHL. PBMCs are collected by leukapheresis for the
Xcellerate™ process, and subjects subsequently receive 2 infusions
of 20–60  109 Xcellerated t cells separated by 6–8 weeks. Ap-
proximately 40 subjects will be treated. Results: Twenty subjects
have been enrolled. The median number of prior treatment regi-
mens was 3 (range, 1–4). Histological subtypes are small lympho-
cytic (n  9), follicular (n  5), mantle cell (n  4), and marginal
zone (n  2). Xcellerated t cells have been manufactured in 15
subjects to date, and 13 subjects have been treated. No related
serious adverse events have been reported to date. Follow-up is
available in 8 subjects through week 6. In these subjects, the
median number of cells infused was 39 109 (range, 33–39 109),
of which 98.9  0.2% were T cells (mean  SD). T-cell counts
increased from 728 56/mm3 before infusion to 1251 953/mm3
on day 28 (mean  SD). All 3 SLL subjects had marked reductions
in peripheral lymphadenopathy on physical examination, and 2 of
these patients also showed decreases on computed tomography
scan. However, the patients did not meet radiographic criteria for
response; 2 of them had bulky abdominal lymphadenopathy. A
bone marrow biopsy specimen obtained in 1 of the SLL subjects
revealed a decrease in leukemic involvement from 70% to 40% of
cellularity. In 2 subjects with follicular lymphoma, 1 had stable
disease radiographically and 1 had disease progression. Three sub-
jects with mantle cell lymphoma had progressive disease. Conclu-
sions: Xcellerated t cells can be manufactured in subjects with
indolent NHL. Treatment leads to signiﬁcant increases in T-cell
counts. Preliminary data suggest a reduction in peripheral lymph-
adenopathy and bone marrow involvement in SLL subjects. Data
on additional subjects will be presented.
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A PHASE I/II STUDY OF XCELLERATED T CELLS AFTER AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS
WITH MULTIPLE MYELOMA
Vij, R.1, Vescio, R.A.2, Borrello, I.M.3, Martin, T.G.4, Siegel, D.5,
Berenson, J.R.6, Janmohamed, F.7, Berenson, R.J.7, Frohlich, M.W.7
1Washington University School of Medicine, St. Louis, MO; 2Cedars-
Sinai Medical Center, Los Angeles, CA; 3Johns Hopkins School of
Medicine, Baltimore, MD; 4University of California, San Francisco,
School of Medicine, San Francisco, CA; 5Hackensack University Medical
Center, Hackensack, NJ; 6Oncotherapeutics, West Hollywood, CA;
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Background: Previous studies have demonstrated a correlation
between survival and lymphocyte recovery following autologous
transplantation in subjects with multiple myeloma and other ma-
lignancies. We initiated a trial in the transplantation setting to
evaluate the activity of T cells activated and expanded ex vivo with
the Xcellerate™ process, which uses anti-CD3 and anti-CD28
antibody–coated magnetic beads (Xcyte™ Dynabeads). Meth-
ods: After induction therapy, patients underwent leukapheresis to
collect peripheral blood mononuclear cells for the Xcellerate™
process. Patients then underwent stem cell mobilization and col-
lection, followed by high-dose melphalan (200 mg/m2). Three days
after peripheral blood stem cell infusion, subjects received 50–
100  109 Xcellerated T cells. Results: A total of 36 subjects were
treated. The median last follow-up visit is 360 days posttransplan-
tation (range, 180–630 days). A WaveBioreactor-based Xcellerate
III™ process, which was instituted in the last 18 subjects, resulted
in a 249-  90-fold (mean  SD) T-cell expansion. An average of
93.6  0.8  109 cells was infused, of which 97.6  4.0% were T
cells. There were no grade 3 or 4 acute infusional toxicities.
Median days of neutropenia and thrombocytopenia were 5 (range,
3–43 days) and 4.5 (range, 0–128 days), respectively. Median days
of hospitalization were 16 (range, 10–70 days). Lymphocyte re-
covery was rapid, with counts reaching  500/mm3 generally
within 1–2 days after T-cell infusion. Historically, lymphocyte
recovery to 500/mm3 usually does not occur for 3 or more weeks
posttransplantation. The rapid lymphocyte recovery included both
CD4 and CD8 T cells. The mean ( SEM) CD4 T-cell
count at 90 days posttransplantation was 1210  80/mm3, which is
signiﬁcantly higher than that for historical controls receiving the
same treatment regimen without Xcellerated T cells (198  72/
mm3). In 35 evaluable patients, preliminary results demonstrated
9% CRs, 51% VGPRs, 29% PRs, and 11% with PD, using the
M-protein at diagnosis as a reference. Conclusions: In multiple
myeloma subjects, administration of Xcellerated T cells after high-
dose chemotherapy and autologous stem cell transplantation leads
to rapid lymphocyte recovery. Most subjects achieve clinical re-
sponses in the autologous transplantation setting.
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HIGH-DOSE MELPHALAN (HDM) WITHOUT HEMATOPOIETIC PROGENI-
TOR CELL (HPC) SUPPORT FOR TREATMENT OF PLASMA CELL LEUKEMIA
Hayek, F.N., Al-Ghawi, H., Mehta, A., Herzig, R.H., Herzig, G.P.
University of Louisville, James Graham Brown Cancer Center, Louis-
ville, KY.
Primary plasma cell leukemia (PPCL) is a rare subtype of mul-
tiple myeloma that follows a rapid clinical course and responds
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poorly to conventional myeloma treatment. Recently it has been
shown that melphalan doses up to 140 mg/m2 without HPC sup-
port can be given safely to myeloma patients. We report our
experience with the use of HDM without HPC support in 3
patients with PPCL. All patients received HDM (140 mg/m2) as a
single 40-minute IV infusion. Filgrastim (6 g/kg/day) was started
24 hours after HDM and continued until absolute neutrophil
count (ANC) was  500/L. There was complete clearance of
plasma cells from the bone marrow and resolution of cytogenetic
abnormalities. IgG level in patient 1 and M-protein level in pa-
tients 2 and 3 decreased by  75% before thalidomide initiation
and was maintained for  6 weeks. One patient (case 1) had
extramedullary disease progression evidenced on day 130 and ex-
pired despite further treatment with VAD, arsenic trioxide, meth-
ylprednisolone, and thalidomide. Patient 2 achieved CR after re-
ceiving allogeneic stem cell transplantation from a matched sibling
donor at day 137 and remains in complete remission. There was no
treatment-related mortality. Treatment of PPCL with HDM with-
out HPC support was well tolerated. It resulted in prompt hema-
tologic recovery and produced dramatic control of an otherwise
rapidly fatal process. Such treatment may be a viable option when
HPC transplantation is not feasible.
Table 1. Patient Characteristics
Age
(y)/
Sex
WBC
(1000/
l)/BM
Involve-
ment
M-protein
Level (g/
dl)/Ig Type
Prior Rx/
Response
Count
Recovery
(D 0)
Thalido-
mide
Started
(D 0)
Best
Documented
Response/
Day (D 0)
TTP/
Survival
(Days)
50/
M
60.5/
100%
Not
available/
IgG
High-dose
cortico-
steroids/
progres-
sive
disease
20 NA PR/120 130/423
45/F 54.6/
100%
3.54/IgG High-dose
cortico-
steroids/
Progres-
sive
disease
20 30 PR/30 NA/557
66/F 17.3/
75%
4.5/IgG VAD/
progres-
sive
disease
36 100 PR/164 NA/219
TTP: time to progression, NA: not applicable, PR: partial re-
sponse.
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BORTEZOMIB DOES NOT ADVERSELY AFFECT STEM CELL MOBILIZA-
TION AND ENGRAFTMENT IN PATIENTS WITH MULTIPLE MYELOMA
UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Uy, G.L., Fisher, N.M., Devine, S.M., Adkins, D.R., Tomasson, M.H.,
Graubert, T.A., DiPersio, J.F., Vij, R. Washington University School of
Medicine, St. Louis, MO.
Bortezomib (Velcade) is a selective inhibitor of the 26S protea-
some approved for the treatment of relapsed or refractory multiple
myeloma (MM). The role of bortezomib in front-line therapy for
MM is undeﬁned and will depend in part on its effects on subse-
quent stem cell mobilization and engraftment. We conducted a
pilot study of bortezomib administered pretransplantation fol-
lowed by high-dose melphalan with autologous hematopoietic
stem cell transplantation (AHSCT). Two cycles of bortezomib 1.3
mg/m2 were administered on days 1, 4, 8, and 11 of a 21-day
treatment cycle. One week after completion of bortezomib, stem
cells were mobilized with G-CSF 10 g/kg/day for 5 days and
harvested by large-volume apheresis (20 L/day) until a minimum of
2.5  106 CD34 cells/kg were collected. Melphalan 100 mg/m2/
day for 2 days was administered, followed by reinfusion of periph-
eral blood stem cells 48 hours later. GM-CSF 250 g/m2/day was
given posttransplantation until neutrophil engraftment occurred.
To date, 32 of a planned 40 patients have been enrolled in this
study, with 23 patients having completed their initial therapy with
bortezomib followed by AHSCT. Prior therapy included both
anthracycline-containing regimens (in 21 patients) and thalido-
mide-containing regimens (in 14 patients). Two patients had not
received prior chemotherapy. All patients successfully achieved the
target of 2.5  106 CD34 cells/kg in either 1 (17 of 23 patients)
or 2 (6 of 23 patients) collections, with the ﬁrst apheresis product
containing a mean of 5.52  106 CD34 cells/kg. Analysis of
lymphocyte subsets by peripheral blood ﬂow cytometry demon-
strated no signiﬁcant differences before and after treatment with
bortezomib. All patients successfully engrafted with a median time
to neutrophil engraftment (ANC  500/mm3) of 11 days (range,
9–14 days). Platelet engraftment (time to platelet count  20,000/
mm3 sustained for 7 days without transfusion) occurred at a median
of 11 days (range, 9–30 days). Seventeen patients were evaluable
for response at 100 days posttransplantation. Compared with pre-
bortezomib paraprotein levels, 5 patients achieved a CR or near
CR, 11 maintained a PR, and 1 patient developed PD. We con-
clude that pretransplantation treatment with 2 cycles of bort-
ezomib given in sequence after anthracycline- or thalidomide-
containing chemotherapy does not adversely affect stem cell yield
or time to engraftment in patients with MM undergoing AHSCT.
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SURVIVAL AFTER AUTOLOGOUS TRANSPLANTATION TO TREAT DIF-
FUSE LARGE B-CELL LYMPHOMA WITH A HISTORY OF CENTRAL NER-
VOUS SYSTEM INVOLVEMENT, BONE MARROW INVOLVEMENT, OR
HISTOLOGICAL TRANSFORMATION
Hayes-Lattin, B., Mehta, P., Dunn, A., Subbiah, N., Leis, J.F.,
Simic, A., Allen, B., Balleisen, S., Curtin, P.T., Epner, E.,
Fleming, W.H., Jacoby, C., Mauro, M.J., Nichols, C.R., Schubach, S.,
Maziarz, R.T. Oregon Health Sciences University Cancer Institute,
Portland, OR.
Background: Patients with diffuse large B-cell lymphoma (DL-
BCL) who present with extranodal involvement or histological
transformation from low-grade disease have lower rates of survival
after conventional-dose therapy. The impact of these features on
outcomes after high-dose therapy with autologous transplantation
was investigated. Methods: We retrospectively reviewed the out-
comes of 64 consecutive patients receiving autologous transplan-
tation from 1995 to 2003 for the treatment of DLBCL. Variables
analyzed were age, gender, histological transformation, history of
bone marrow involvement, history of central nervous system
(CNS) involvement, time from diagnosis to transplantation, num-
ber of pretransplantation regimens, chemosensitivity before trans-
plantation, conditioning regimen, year of transplantation, and the
use of peripheral blood or bone marrow stem cells. Survivals were
estimated by the Kaplan-Meier method. The Cox proportional
hazards regression model was used to test the signiﬁcance of factors
on survival. Correlation between variables was tested with Spear-
man’s rank coefﬁcient. Results: The median age at transplantation
was 53.5 years. The median overall survival was 3.3 years, disease-
free survival was 1.2 years, and 100-day mortality was 7%. Among
a total of 29 patients, 12 had a history of CNS involvement, 10 had
a history of bone marrow involvement, and 12 had transformed
from low-grade lymphoma. A Cox regression analysis performed
to assess multivariate factors for survival suggested 2 regimens
before transplantation (log-rank test, P  .05) and the lack of
BEAM as the conditioning regimen (log-rank test, P  .02) as
signiﬁcant for overall survival. However, the use of BEAM was
highly associated with older age (r2  .42; P  .001) and more
prior chemotherapy regimens (r2 .24; P  .05). A history of
extranodal involvement, including prior CNS involvement (P 
.84) or bone marrow involvement (P  .52), was not associated
with lower survival by univariate analysis. No signiﬁcant associa-
tion was found between survival and a history of transformation
(P  .48). Conclusions: A history of CNS involvement, bone
marrow involvement, or histological transformation was not asso-
ciated with lower rates of survival among patients undergoing
autologous transplantation for DLBCL. Patients who present with
these clinical presentations remain candidates for autologous trans-
plantation.
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